Floatz logo

WNT-974

BRAF Mutant Colorectal Cancer

Novartis PharmaceuticalsSmall moleculePhase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
95/ 100

Competitive context

840 Active assets in the BRAF Mutant Colorectal Cancer cohort.

Asset / SponsorPhaseRating
Desflurane
Peter MacCallum Cancer Centre, Australia
Phase 4BBB
MARBLE DUST
James Varani
Phase 2/3BB
FLUOROURACILUM
Washington University School of Medicine
Phase 4BB
PANITUMUMAB
M.D. Anderson Cancer Center
Phase 3BB
Cetuximab
Shanghai Henlius Biotech
Phase 4BB

View all 50 →

Same molecule, other indications

WNT-974 is also rated in:

cervical squamous cell carcinomaDormant
CC
Indicative ·
47 / 100
View asset →
squamous cell lung carcinomaDormant
CC
Indicative ·
47 / 100
View asset →
head and neck squamous cell carcinomaDormant
CC
Indicative ·
46 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →